Nitazoxanide

Generic Name: Nitazoxanide

Brand Names: Alinia, Busulfex

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₉N_₃O_₅S

CAS Number: 55981-09-4

Unique Ingredient Identifier: SOA12P041N

Background: Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment o...

Indication: 用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。

Associated Conditions: Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia

Associated Therapies: -

Clinical Trials

Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Nitazoxanide
Biological: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2007-01-12

Last Posted Date: 2008-09-25

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 121

Registration Number: NCT00421434

Locations: 🇪🇬
Department of Tropical Medicine & Infectious Diseases, Alexandria University, Alexandria, Egypt
🇪🇬
Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine, Tanta, Egypt

Study of Nitazoxanide in the Treatment of Chronic Hepatitis C

Phase 2

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2007-01-05

Last Posted Date: 2007-01-05

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 50

Registration Number: NCT00418639

Locations: 🇪🇬
Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine, Tanta, Egypt
🇪🇬
Cairo Liver & GIT Center, Cairo, Egypt
🇪🇬
Department of Tropical Medicine & Infectious Diseases, Alexandria University, Alexandria, Egypt

Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis

Phase 2

Completed

Conditions: Clostridium Difficile

First Posted Date: 2007-01-04

Last Posted Date: 2007-01-04

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 114

Registration Number: NCT00417872

Locations: 🇺🇸
WellStar Infectious Diseases, Marietta, Georgia, United States
🇺🇸
The Reading Hospital and Medical Center, West Reading, Pennsylvania, United States
🇺🇸
Remington-Davis, Inc., and Riverside Infection Consultants, Inc., Columbus, Ohio, United States

and more 4 locations

Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

Phase 3

Terminated

Conditions: Clostridium Infections

Interventions: Drug: Nitazoxanide
Drug: Vancomycin

First Posted Date: 2006-10-06

Last Posted Date: 2015-05-05

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 50

Registration Number: NCT00384527

Locations: 🇺🇸
Michael E. Debakey VAMC, Houston, Texas, United States
🇺🇸
Bay Pines VAMC, Bay Pines, Florida, United States
🇺🇸
John D. Dingell VAMC, Ann Arbor, Michigan, United States

and more 7 locations

Study of Nitazoxanide in the Treatment of Amebiasis in Children

Phase 3

Completed

Conditions: Amebiasis

First Posted Date: 2006-08-21

Last Posted Date: 2006-08-21

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 50

Registration Number: NCT00366730

Locations: 🇪🇬
Benha University Hospital, Benha, Egypt
🇪🇬
University Hospital, Alexandria, Egypt

Study of Nitazoxanide in the Treatment of Amebiasis in Adults and Adolescents

Phase 3

Completed

Conditions: Amebiasis

First Posted Date: 2006-08-21

Last Posted Date: 2006-08-21

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 50

Registration Number: NCT00366236

Locations: 🇪🇬
Benha University Hospital, Benha, Egypt
🇪🇬
University Hospital, Alexandria, Egypt

Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection

Phase 3

Completed

Conditions: Pseudomembranous Colitis
Clostridium Enterocolitis

Interventions: Drug: Nitazoxanide

First Posted Date: 2006-03-17

Last Posted Date: 2017-12-15

Lead Sponsor: Daniel M. Musher MD

Target Recruit Count: 22

Registration Number: NCT00304356

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Michael E. Debakey VA Medical Center, Houston, Texas, United States

Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Other: Placebo
Drug: Nitazoxanide

First Posted Date: 2005-08-15

Last Posted Date: 2012-05-31

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 98

Registration Number: NCT00130390

Locations: 🇺🇸
Gastrointestinal Associates, LLC, Kingsport, Tennessee, United States
🇺🇸
Nashville Medical Research, Nashville, Tennessee, United States
🇺🇸
Romark Laboratories, L.C., Tampa, Florida, United States

and more 9 locations

Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children

Phase 1

Completed

Conditions: HIV Infections
Cryptosporidiosis

First Posted Date: 2003-02-20

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 6

Registration Number: NCT00055107

Locations: 🇹🇭
Siriraj Hospital Mahidol University CRS, Bangkok, Thailand
🇿🇦
Stellenbosch Univ. CRS, Cape Town, South Africa

Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients

Phase 3

Terminated

Conditions: Cryptosporidiosis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 30

Registration Number: NCT00004986

Locations: 🇺🇸
Julie Ryner, Tampa, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy